Novel Small Molecule Antagonists of the Interaction of the Androgen Receptor and Transcriptional Co-regulators
Abstract
Androgens, mediated by the Androgen Receptor (AR), play a crucial role in prostate cancer. Current treatments include antiandrogens competing with natural androgens and antagonize AR transcriptional activity. Although widely used, antiandrogens have shown significant side effects. Regulation of gene expression by AR requires the binding to its natural ligand, dihydrotestosterone (DHT), and assembly of coregulatory proteins (CoR). The blockage of the interaction between DHT-liganded AR and CoR by small molecules has been shown to inhibit gene transcription. Targeting this interaction might be a relevant way to regulate prostate cancer proliferation. Preliminary data revealed that flufenamic acid (FLF) binds to AR and inhibit the recruitment of CoR. We have synthesized a series of FLF analogs, evaluated their solubility, cell permeability and cytotoxicity profiles. We report the biochemical activity of these compounds towards their ability to block CoR binding. In cell based assays, we show the bioactivity of these inhibitors at a gene transcription level. Thus, we provide the first class of small molecules able to inhibit AR transcription activity. Additionally, we optimized an AR scintillation proximity (SPA) competition ligand binding assay. We showed that this assay can be used to measure ligand affinities for a range of nuclear receptors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 31, 2008
- Accession Number
- ADA481881
Entities
People
- Clementine Feau